Drugs / Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1
Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07208539 | Oct 2025 → Apr 2026 overdue | malignant pancreatic neoplasm | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07208539 ↗ |